Switzerland's Article 8 exceptional-authorization pathway has allowed MDMA- and psilocybin-assisted therapy for patients for over a decade — Europe's longest-running program.
Article 8(5) of the Swiss Federal Act on Narcotics and Psychotropic Substances (Betäubungsmittelgesetz, BetmG) allows the Federal Office of Public Health (FOPH, also known as BAG in German) to grant individual exceptional-use permits for otherwise prohibited substances, including psychedelics.
Under normal Swiss law, substances listed in Article 8(1) — including MDMA, psilocybin, and LSD — cannot be produced, held, or used. The compassionate use exemption carves out a narrow exception: a licensed physician can apply for a named-patient authorization when no other treatment option remains.
The FOPH began issuing these authorizations for psychedelic therapy in 2014, making Switzerland the world's first country to sustain a continuous legal psychedelic therapy program for patients — years before Australia's rescheduling in 2023 or Canada's Special Access Program amendment in 2022.
A 2012 revision to the Narcotics Act clarified that Article 8(5) covered limited medical use, not just scientific research. This gave the FOPH the explicit basis to approve patient-by-patient treatment applications — not just research protocols.
The timing also followed the completion of Dr. Peter Gasser's Swiss-based LSD trial (2007–2012), which produced the first published evidence of therapeutic LSD use in over 40 years. That data gave FOPH the safety record it needed to start approving individual patient cases.
A treating physician submits the application to the FOPH on the patient's behalf — patients cannot apply directly. The FOPH reviews each case individually and issues authorization for a specific substance, dose range, and treatment period.
The application must include the patient's diagnosis, the clinical rationale for psychedelic treatment, the planned dosage, and the patient's signed consent form. The physician must also commit in writing to submitting interim progress reports during and after treatment.
Authorization is granted only if four conditions are met: the patient has a largely incurable disease; the substance can reduce suffering; all conventional treatments have been tried without sufficient benefit; and the treatment is expected to improve the patient's autonomy and quality of life.
Once the FOPH approves the application, the physician can legally obtain the controlled substance from a Swiss-licensed pharmacy or importer. Treatment typically involves one to four substance sessions within a 12-month period, each paired with preparation and integration psychotherapy appointments.
The physician must submit a progress report at least once during the authorization period. The FOPH may revoke the authorization if safety concerns arise or if the physician fails to report.
MDMA, psilocybin, and LSD are all authorized under Switzerland's Article 8 program. Each requires a separate named-patient authorization, and a physician may hold multiple authorizations for different substances simultaneously.
MDMA and LSD were the first to be authorized in 2014, following the completion of Swiss clinical studies for both. Psilocybin was added to the program in 2021 after early trial data from Switzerland and abroad supported its safety profile.
By 2024, the three substances had the following patient distribution under active authorizations:
Psilocybin's rise to the top spot reflects the global wave of clinical trial data after 2019. More physicians and patients became familiar with it through media coverage of trials in the UK and US, which drove a shift in authorization requests toward psilocybin. For a substance overview, see our psilocybin guide and MDMA guide.
The Swiss Medical Society for Psycholytic Therapy (SITP, or Schweizerische Ärztegesellschaft für Psycholytische Therapie) is the professional body that trains and supports physicians working in Switzerland's Article 8 program. Dr. Peter Gasser has served as president since 1996.
Gasser's clinical work is what made the 2014 program launch possible. Between 2007 and 2012, he ran a double-blind, randomized, active-placebo-controlled pilot study with 12 terminally ill patients with anxiety. The trial used two LSD-assisted psychotherapy sessions separated by two to three weeks, alongside non-drug therapy sessions.
The results, published in the Journal of Nervous and Mental Disease in 2014, showed that state anxiety scores at two months were significantly lower in the LSD group than in the placebo group. A 12-month follow-up showed lasting benefits with no serious adverse events. It was the first published therapeutic LSD study in over 40 years worldwide.
The SITP runs structured training for physicians who want to practice psycholytic therapy. Training includes pharmacology, supervised clinical experience, and personal experience with the substance. This last requirement is operationally unusual: Switzerland expects physicians to have direct experiential knowledge of the medicine they prescribe.
This training model is one detail that rarely appears in international comparisons of compassionate use programs. In Australia and Canada, physician training standards for authorized prescribers are set by the regulator and do not include a personal-experience requirement. The SITP approach reflects a distinctly European tradition of psycholytic therapy that traces back to Stanislav Grof's work.
Switzerland's Article 8 psychedelic therapy program has grown from two authorized physicians in 2014 to approximately 100 by 2024 — a 50-fold increase over a decade. The program delivered roughly 1,660 individual substance-assisted sessions in 2024 alone.
Treatment sites now include the Geneva University Hospitals (HUG), Bethesda Spital Basel, the University Psychiatric Clinics of Basel and Bern, centers in Fribourg and Zurich, and a distributed network of individual psychiatrists and psychotherapists in private practice.
The program operates without public funding. Swiss national health insurance does not cover MDMA, psilocybin, or LSD therapy, so patients pay out of pocket. A full course of therapy — including preparation, one to four substance sessions, and integration psychotherapy — typically costs several thousand Swiss francs, placing it out of reach for many patients who might qualify medically.
Switzerland, Australia, and Canada are the three countries with the most developed formal compassionate access pathways for psychedelic therapy. Each takes a meaningfully different approach on eligibility, substances, and oversight.
| Feature | Switzerland (Art. 8) | Australia (TGA Authorised Prescriber) | Canada (Health Canada SAP) |
|---|---|---|---|
| Program start | 2014 | July 2023 | January 2022 |
| Authorized substances | MDMA, psilocybin, LSD | MDMA, psilocybin | Psilocybin, MDMA (case-by-case) |
| Eligible diagnoses | Any serious condition; no fixed list | PTSD (MDMA); treatment-resistant depression (psilocybin) | Any serious condition with no alternative |
| Ethics approval required? | No — individual patient authorization only | Yes — ethics approval from an HREC required | No — physician applies directly to Health Canada |
| Prescriber type | Licensed physician (SITP-trained preferred) | Authorized Prescriber — must be a psychiatrist | Any licensed physician |
| Insurance coverage | None | None (some private coverage emerging) | None |
| LSD authorized? | Yes | No | No |
| Program status | Active — growing | Active — expanding since 2023 | Active — slower uptake |
When Switzerland fits best: patients with serious conditions who cannot be categorized under Australia's narrow diagnosis list, or who want access to LSD-assisted therapy. Switzerland also works for patients who already have a relationship with a Swiss-trained SITP physician.
When Australia fits better: patients with confirmed PTSD or treatment-resistant depression who want the most structured, psychiatrist-led pathway with growing institutional support. See our Australia psychedelic rescheduling guide for details on that program.
When Canada fits better: Canadian residents who need psilocybin or MDMA access but cannot travel. For a direct comparison, see our Health Canada SAP guide.
Switzerland's Article 8 program is individual-patient medicine, not a regulated therapeutic market. It does not create a legal retail pathway, licensed retreat centers, or a lay-facilitator model.
Only licensed Swiss physicians can apply for authorization. International patients traveling to Switzerland for psychedelic therapy face a significant practical barrier: they need an established clinical relationship with a Swiss-licensed physician who holds or can obtain an Article 8 authorization. There is no Swiss equivalent of Oregon's healing-center model, where any adult can book a session.
The program also does not decriminalize personal possession. Outside the authorized treatment setting, MDMA, psilocybin, and LSD remain prohibited substances under Swiss law. For global context on where psychedelics are decriminalized versus therapeutically authorized, see our guide to legal psychedelics in the US and the psychedelic legalization tracker.
Yes, psychedelic therapy is legal in Switzerland for qualifying patients under Article 8(5) of the Narcotics Act. The Federal Office of Public Health (FOPH/BAG) grants individual treatment authorizations to licensed physicians. Patients must have a serious condition, have exhausted conventional treatments, and provide written consent.
Switzerland's Article 8 limited medical use program authorizes MDMA, psilocybin, and LSD for use in individual patient therapy. As of 2024, psilocybin has become the most authorized substance with 348 patients, followed by MDMA with 245 patients and LSD with 130 patients.
A treating physician applies to the FOPH on behalf of the patient. The application must include the diagnosis, justification for treatment, dosage plan, and the patient's written consent. The FOPH reviews each case individually. The physician must also commit to submitting progress reports during treatment.
Switzerland's Article 8 psychedelic therapy program has been running since 2014, making it the world's longest continuously operating legal psychedelic therapy program. It started with just two authorized physicians and has grown to approximately 100 physicians treating over 700 patients as of 2024.
Switzerland's Article 8 program does not restrict access to specific diagnoses and does not require ethics board approval for individual treatment. Australia's TGA Authorised Prescriber Scheme is limited to PTSD and treatment-resistant depression, and Canada's SAP was only amended to include psychedelics in 2022. Switzerland predates both by years.
Dr. Peter Gasser was the first physician to receive authorization for LSD-assisted psychotherapy under Switzerland's compassionate use framework. From 2007 to 2012, Gasser conducted the first therapeutic LSD study in over 40 years, treating anxiety in terminally ill patients. He has held Article 8 authorizations since 2014.
No. Swiss national health insurance does not cover MDMA, psilocybin, or LSD therapy sessions. Patients pay out of pocket. A full treatment course — including preparation sessions, one to four substance sessions, and integration — typically costs several thousand Swiss francs.
SITP stands for the Swiss Medical Society for Psycholytic Therapy (Schweizerische Ärztegesellschaft für Psycholytische Therapie). It is the professional body for physicians trained in psycholytic and psychedelic therapy. Dr. Peter Gasser has served as president since 1996. The SITP promotes training standards and advocacy for the program.
In practice, Switzerland's program is designed for patients receiving ongoing care from a Swiss-licensed physician. The authorization is issued to the treating doctor, not the patient. International patients without an established relationship with a qualifying Swiss physician will find it very difficult to access the program through tourism.
By 2024, approximately 100 physicians held active authorizations, with about 723 patients receiving treatment — and roughly 1,660 individual substance-assisted sessions in that year alone. The program has grown significantly from its starting point of two authorized physicians in 2014.
Yes. LSD has been authorized for individual patient therapy under Switzerland's Article 8 framework since 2014. As of 2024, approximately 130 patients were receiving LSD-assisted therapy — the smallest of the three authorized substances by patient count, but notable because LSD therapy was entirely prohibited in clinical settings globally for decades before Switzerland revived it.
The legal basis is Article 8(5) of the Swiss Federal Act on Narcotics and Psychotropic Substances (Betäubungsmittelgesetz, BetmG). This provision allows the Federal Office of Public Health to grant exceptional use permits for substances otherwise prohibited under Art. 8(1). The 2012 amendment explicitly extended this pathway to limited medical use cases.
Our real-time tracker covers Switzerland's program alongside Australia, Canada, and every US state with active legislation — updated as authorizations, votes, and rule changes happen.
Get Switzerland Art. 8 Narcotics Act — Psychedelic Compassionate Use updates
New votes, rules, court rulings, and access changes for Switzerland Art. 8 Narcotics Act — Psychedelic Compassionate Use — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.